Peripheral neuropathy (PN) is the most troublesome adverse event associated with the proteasome inhibitor bortezomib. Studies suggest an inflammatory aetiology for bortezomib-induced PN (BiPN) and it has been hypothesized that reducing inflammation with concomitant dexamethasone may reduce BiPN incidence and/or severity. We retrospectively analysed PN rates from 32 studies (2697 patients with previously untreated multiple myeloma) incorporating bortezomib and differing dexamethasone schedules: partnered dosing (days of and after bortezomib), weekly dosing, and other dosing schedules (e.g. days 1-4, 8-11). Pooled overall PN rates were 45Á5%, 63Á9%, and 47Á5%, respectively, with 5Á3%, 11Á0%, and 9Á6% grade ≥3. Adjusting for potential confounders (age, gender, presence of thalidomide, bortezomib treatment duration), PN rates in patients on partnered dosing schedules appeared lower than in patients on weekly or other dosing schedules. Analyses conducted using patient-level data suggest that cumulative dexamethasone dose, a potential confounding factor, is unlikely to have influenced the analyses. Findings were similar in a separate pooled analysis excluding data from regimens incorporating thalidomide, when pooled overall PN rates were 50Á1%, 63Á9%, and 48Á3%, respectively, with 4Á2%, 11Á0%, and 8Á6% grade ≥3. These findings suggest that partnered dexamethasone dosing may result in less severe BiPN compared with alternative dexamethasone dosing schedules.
and weekly, respectively, indicated similar overall PN rates (80% vs. 71%) but lower grade ≥3 PN rates with concomitant versus weekly dexamethasone (2% vs. 17%) (Richardson et al, 2010; Kumar et al, 2012) . We therefore analysed PN rates from multiple studies of regimens incorporating bortezomib and differing dexamethasone schedules in patients with previously untreated MM. were conducted to identify non-retrospective studies of all combination regimens incorporating bortezomib and dexamethasone. Studies were manually selected for inclusion using the following criteria: bortezomib administered intravenously (1Á3 mg/m 2 twice weekly; days 1, 4, 8 and 11; 21-day cycles), ≥20 previously untreated MM patients, and data reported on overall and/or grade ≥3 PN/sensory PN rates. Studies were categorized based on the dexamethasone dosing schedule: partnered dosing, day of/ after bortezomib (days 1, 2, 4, 5, 8, 9, 11 and 12); weekly dosing (days 1, 8, and 15); other schedules (days 1-4, 8-11, and similar). Only clinical trials in newly diagnosed MM patients were included to reduce possible bias related to prior neurotoxic drug exposure. Studies utilizing bortezomib maintenance in which PN rates were not reported separately for bortezomib induction schedules were excluded.
Methods

Clinical trial selection
Statistical analysis
Pooled grade ≥3/all-grade PN rates were derived for each dexamethasone schedule by dividing the total number of patients experiencing grade ≥3/all-grade PN by the total number of patients on the dexamethasone schedule. Adjusted logistic regression was conducted to account for potential confounding factors on a study-level (meta-analysis), including age (average or median), gender (proportion of males), whether the study regimen incorporated thalidomide, and duration of bortezomib treatment (average or median number of cycles). The adjusted odds of grade ≥3/all-grade PN in weekly and other dexamethasone dosing schedules were compared to the partnered schedule, including 95% confidence intervals (CI) for odds ratios and chi-square P values. Additional analyses in two studies from which patientlevel data were available were conducted, aiming to account for potential biasing/confounding factors, such as cumulative dose of dexamethasone and duration of bortezomib treatment. Analysis of the relationship between duration of therapy and PN rates using different dexamethasone schedules was also performed.
Results
We identified 14 (1416 patients) (Einsele et al, 2009; Jagannath et al, 2009; Jakubowiak et al, 2009 Jakubowiak et al, , 2011 Kropff et al, 2009; Zheng et al, 2009; Bensinger et al, 2010; Cavo et al, 2010 Cavo et al, , 2014 Richardson et al, 2010; Joshua et al, 2012; Kaufman et al, 2012; Landau et al, 2012; Nishihori et al, 2015) , three (191 patients) (Gozzetti et al, 2010; Kumar et al, 2012; Roussel et al, 2014) , and 15 (1090 patients) (Harousseau et al, 2006 (Harousseau et al, , 2010 Wang et al, 2007 Wang et al, , 2010 Popat et al, 2008; Corso et al, 2010; Eom et al, 2010; Palumbo et al, 2010; Reeder et al, 2010; Chen et al, 2011; Moreau et al, 2011b; Kim et al, 2012; Rosinol et al, 2012 Rosinol et al, , 2014 Gay et al, 2013; Ludwig et al, 2013) studies using partnered, weekly or other dexamethasone dosing schedules, respectively (Table I) .
Pooled overall PN grade ≥3 rates for partnered, weekly and 'other' studies were 5Á3%, 11Á0% and 9Á6%, respectively (Table II) . Compared to patients on partnered dosing schedules, patients on weekly or 'other' dexamethasone schedules had significantly higher odds of grade ≥3 PN (weekly vs partnered adjusted odds ratio [OR], 1Á60; 95% CI 0Á89, 2Á88; P = 0Á12; other vs partnered adjusted OR, 1Á44; 95% CI 1Á03, 2Á02; P = 0Á03). An increased OR of grade ≥3 PN was also observed for studies that incorporated thalidomide into their regimen compared with studies that did not (adjusted OR, 1Á62; 95% CI 1Á16, 2Á26; P < 0Á01). No other potential confounding factor was found to be associated with grade ≥3 PN.
To investigate the potential confounding effect of thalidomide on PN rates, a separate pooled analysis was conducted that excluded studies with regimens incorporating thalidomide (Table II) . Pooled PN grade ≥3 rates for partnered, weekly and 'other' dexamethasone schedules were 4Á2%, 11Á0% and 8Á6%, respectively. Adjusted for potential confounders, the ORs comparing weekly and 'other' to partnered schedule grade ≥3 PN were 1Á66 (95% CI 0Á88, 3Á13; P = 0Á11) and 1Á60 (95% CI 1Á01, 2Á55; P = 0Á05), respectively. Grade ≥3 PN rates excluding studies with thalidomide appeared to be consistent with the overall analysis, showing reduced risk of grade ≥3 PN with the partnered schedule.
The pooled overall all-grade PN rates for partnered, weekly and 'other' studies were 45Á5%, 63Á9% and 47Á5%, respectively (Table II) . Adjusting for potential confounding factors, the ORs comparing all-grade PN for weekly and 'other' dexamethasone schedules with partnered schedules were 0Á99 (95% CI 0Á65, 1Á50; P = 0Á95) and 0Á88 (95% CI 0Á71, 1Á09; P = 0Á24), respectively.
When studies incorporating thalidomide were excluded, pooled all-grade PN rates for partnered, weekly and 'other' dexamethasone schedules were 50Á1%, 63Á9% and 48Á3%. Adjusting for potential confounders, the ORs comparing allgrade PN for weekly and 'other' dexamethasone schedules versus partnered were 1Á49 (95% CI 0Á96, 2Á32; P = 0Á08) and 0Á94 (95% CI 0Á73, 1Á20; P = 0Á63). An increase in the median number of bortezomib treatment cycles was associated with a significant increase in the odds of all-grade PN, with and without the studies incorporating thalidomide (P < 0Á000000001). This observed relationship between duration of bortezomib treatment and risk of all-grade PN, coupled with the fact that patients on partnered dosing schedules generally received fewer cycles of bortezomib treatment than patients on weekly and 'other' studies, may explain why, after adjusting for potential confounders, there was no consistent trend supporting a decreased risk of all-grade PN with the partnered schedule. Figure 1 illustrates the associations between duration of bortezomib treatment, dexamethasone schedule, grade ≥3 PN and all-grade PN. Table III shows the ranges of response rates seen across the studies, according to dexamethasone dosing schedule; ranges are presented due to study heterogeneity in terms of patient characteristics and treatment regimens. For each type of dexamethasone schedule, overall response rates (ORR) of up to 100% were reported, with CR rates ranging from between 7% and 40% with a partnered schedule to between 12% and 58% with 'other' dexamethasone schedules.
Using patient-level data from the phase I/II RVD study (n = 66) with partnered dexamethasone dosing (Richardson et al, 2010) and the EVOLUTION study (n = 140) with weekly dexamethasone dosing (Kumar et al, 2012) , the impact of potential confounding factors, such as cumulative dose of dexamethasone and duration of bortezomib treatment, was evaluated. The median cumulative dexamethasone dose was 960 and 680 mg, respectively, due to the difference in the median number of treatment cycles (eight and six, respectively). Among patients with grade ≥3 BiPN (RVD, n = 2; EVOLUTION, n = 19), the median cumulative dexamethasone dose was similar, at 695 and 720 mg, respectively, and the median cumulative dose before the onset of BiPN was 695 and 440 mg, respectively. In EVOLUTION, median cumulative dexamethasone dose was similar between patients with and without grade ≥3 BiPN (720 and 680 mg, respectively).
Similarly, the impact of duration of bortezomib treatment was evaluated. Analysis of patient-level data from the phase I/II RVD and EVOLUTION studies showed that patients received a median of eight (range 2-33) and six (1-12) cycles of bortezomib, respectively. Among patients with grade ≥3 BiPN, the number of bortezomib cycles was four and eight in the two patients on the phase I/II RVD study, and the median number of cycles was four (2-12) in EVOLUTION. Further, the median time to onset of grade ≥3 BiPN was similar in the phase I/II RVD and EVOLUTION studies, at 78 and 86 days, respectively.
Discussion
This retrospective analysis of IV bortezomib studies suggests that partnered dexamethasone dosing may result in less severe BiPN compared with alternative concomitant dexamethasone dosing schedules. The partnered dexamethasone schedule was consistently associated with a lower rate of all grade and grade ≥3 PN compared with weekly and 'other' schedules; a finding that held true regardless of the inclusion of thalidomide, which is independently associated with PN development. Thus, although the inclusion of studies of bortezomib-dexamethasone regimens incorporating thalidomide was a potential biasing/confounding factor, it did not appear to influence the findings.
In terms of other potential confounding factors, data from the phase III VISTA and APEX studies demonstrated that the risk of BiPN was dose-related and cumulative up to a rate plateau, which was seen at a cumulative bortezomib dose of approximately 42-45 mg/m 2 (the equivalent of approximately eight 21-day cycles) (Richardson et al, 2009; Dimopoulos et al, 2011) . In both studies, the majority of PN occurred by a cumulative bortezomib dose of approximately 26 mg/m 2 , the equivalent of five 21-day cycles. Furthermore, based on the phase I/II RVD and EVOLUTION studies (Richardson et al, 2010; Kumar et al, 2012) , the level of grade ≥3 PN appeared higher for weekly/other dosing compared with partnered dexamethasone dosing and appears to depend on duration of treatment, as seen in analyses of time to onset in phase III studies of bortezomib (Richardson et al, 2009; Dimopoulos et al, 2011; Arnulf et al, 2012) . However, our analyses showed that neither cumulative bortezomib dose nor duration of bortezomib therapy presented viable alternative hypotheses for our findings. Additionally, it is notable that previous BiPN analyses, including in the phase III VISTA and APEX studies, have not identified any disease-or 95% CI, 95% confidence interval; OR, odds ratio; PN, peripheral neuropathy. *Partnered: dexamethasone given on day of/after bortezomib; weekly: dexamethasone given once per week; other: dexamethasone given on days 1 -4 AE 8-11/9-12 (or similar). † Based on studies reporting rates of all-grade PN. ‡ Adjusted for age, gender, whether the study regimen incorporated thalidomide, and number of cycles of bortezomib. (Richardson et al, 2006 (Richardson et al, , 2009 Dimopoulos et al, 2011) . Differences in neuropathy did not appear to be associated with notable efficacy differences. Owing to study heterogeneity in terms of patient characteristics and treatment regimens, it was only possible to report ranges of response rates across studies, according to dexamethasone dosing schedule. The overlapping response ranges however, suggest no inter-schedule differences.
Multiple mechanisms have been proposed for BiPN, and evidence suggests an inflammatory mechanism. Partnered dexamethasone dosing may mitigate the role of proinflammatory genes and inflammatory cytokines in BiPN development; dexamethasone-based therapy has been shown to reduce levels of proinflammatory cytokines, including tumour necrosis factor a (TNF-a), interleukin (IL)6, and IL8 (Kuku et al, 2005) . Inflammatory cascade activation and proinflammatory cytokine upregulation have been implicated in chemotherapy-induced PN with multiple drugs including bortezomib (Wang et al, 2012) ; notably, TNF-a, IL1b, IL6, and CCL2 have been implicated in neuropathic pain. In animal studies, IL6, TNF-a, transforming growth factor-b1 (TGF-b1) and IL1b upregulation was seen in dorsal root ganglia, with TNF-a and IL6 levels being highest; moreover, treatment with anti-TNF-a, but not anti-IL6, significantly prevented sensory nerve action potentials, amplitude decreases and myelinated/unmyelinated fibre loss (Ale et al, 2014) . In another study, bortezomib upregulated TNF-ɑ and phosphorylated JNK1/2 expression in rat dorsal root ganglia . Interestingly, thalidomide, presumably via TNF-ɑ inhibition, blocked JNK1/2 activation in ganglia and attenuated neurological effects following bortezomib treatment. TNF-a receptors, TNFR1 or TNFR2 knockouts in mice inhibited JNK1/2 activation and attenuated bortezomib effect. These findings may also explain, to some extent, the relatively lower degree of neuropathy seen with bortezomibthalidomide-dexamethasone than would be expected when combining two drugs associated with PN. Others have reported PN improvement with plasma exchange and steroid therapy, again pointing to an immune-based mechanism (Schmitt et al, 2011; Jeter & Kang, 2012) . Broyl et al (2010) analysed single nucleotide polymorphisms (SNPs) in DNA samples from 369 patients from phase III trials. Among 63 patients developing late-onset BiPN, significant differences among SNPs were noted in inflammatory genes MBL2 and PPARD, and DNA repair genes ERCC4 and ERCC3. These genes differed from those observed with vincristine-induced PN, suggesting a specific role in BiPN. Similarly, Favis et al (2011) identified SNPs in genes related to immune function (CTLA4, CTSS), reflexive coupling within Schwann cells (GJE1), drug binding (PSMB1), and neuron function (TCF4, DYNC1I1) associated with BiPN (Favis et al, 2011) . This analysis was limited by the heterogeneity of the studies, which prevents definitive conclusions being drawn. In addition, the analysis did not take into account baseline PN levels, which, as mentioned above, has been shown to be associated with subsequent PN development.
In conclusion, the findings of this retrospective analysis suggest partnered dexamethasone dosing may result in less severe BiPN compared with alternative concomitant dexamethasone dosing schedules. These findings require confirmation with further analyses to account for confounding factors. However, if demonstrated, this could provide an important contribution in terms of supportive care of MM patients for managing BiPN. Regardless, regular monitoring and early detection and intervention remain of key importance for managing BiPN .
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